Add to Favourites
To login click here
Lantern Pharma Inc. (NASDAQ: LTRN), a biopharmaceutical company utilizing its proprietary RADR AI and ML platform to revolutionize the cost, speed, and timeline of oncology drug discovery and development, has released new data for its product candidate LP-100. The data supports the development of LP-100 in combination with PARP inhibitors, demonstrating synergistic potency in prostate cancer mouse xenograft studies and ovarian cancer cell line studies. The observations are further supported by in-silico evaluation of LP-100 in combination with PARP inhibitors using Lantern’s AI platform, RADR.
